Polatuzumab

Introduction

Polatuzumab is a targeted cancer therapy used in the treatment of certain types of B-cell lymphomas, especially diffuse large B-cell lymphoma (DLBCL) that has not responded to other treatments. It belongs to a class of medicines called antibody-drug conjugates and is administered as part of a combination regimen with other chemotherapy agents. Polatuzumab works by directly delivering chemotherapy to cancer cells, helping to reduce tumor size and slow disease progression. It is typically used in patients with relapsed or refractory lymphoma.

Uses of Polatuzumab

• Treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
• Used in combination with other chemotherapy agents
• Applied when other cancer treatments have failed

How Polatuzumab works

Polatuzumab targets CD79b, a protein found on B cells, and delivers a chemotherapy drug directly into the cancer cells. This action kills the cancerous B cells while limiting damage to surrounding healthy cells, making the treatment more precise and effective.

Benefits of Polatuzumab

• Targeted action against cancer cells
• Effective in hard-to-treat lymphoma cases
• Reduces tumor size and slows progression
• Improves treatment outcomes when combined with other drugs
• Helps patients who no longer respond to standard therapies

How to take Polatuzumab

Polatuzumab is administered as an intravenous (IV) infusion in a clinical setting under the supervision of a healthcare professional. The dosage and schedule depend on body weight and other medical conditions. It is usually given every 21 days for a specific number of cycles. Pre-medication may be given to reduce infusion-related reactions.

Type of Dosage Available

• Injection (Intravenous Infusion)

Side effects of Polatuzumab

• Fatigue
• Nausea and vomiting
• Low white blood cell count (neutropenia)
• Peripheral neuropathy (tingling or numbness)
• Fever and infections
• Infusion-related reactions
• Liver enzyme changes

Safety advice

• Only to be used under medical supervision
• Inform your doctor about any existing liver conditions
• Avoid live vaccines during treatment
• Regular blood tests are required to monitor blood counts and liver function
• Discuss use in pregnancy or breastfeeding with your doctor
• Report any signs of infection or neuropathy promptly

Frequently Asked Questions (FAQs)

Q. What is Polatuzumab used for?
A. Polatuzumab is used to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL), usually in combination with other chemotherapy drugs.

Q. How is Polatuzumab administered?
A. It is given as an intravenous infusion by a healthcare provider, typically every three weeks.

Q. Is Polatuzumab a chemotherapy drug?
A. It is a targeted therapy that combines a monoclonal antibody with a chemotherapy agent, making it more selective for cancer cells.

Q. Can Polatuzumab be used alone?
A. No, it is usually used in combination with other chemotherapy agents for better effectiveness.

Q. Are there any serious side effects?
A. Serious side effects include low blood cell counts, nerve damage, liver issues, and infusion-related reactions. Regular monitoring is essential.